It must be that I have been reading about such things a lot recently. If it is hand crafted than it shows humans are still edging out the robots for now..
> On Apr 1, 2021, at 12:18 PM, Alex Balashov <[email protected]> wrote: > > Let me make sure I understand your question correctly: it is your belief or > conjecture that this press release was automatically generated by a machine > learning system? > > — > Sent from mobile, with due apologies for brevity and errors. > >> On Apr 1, 2021, at 3:10 PM, Brandon Svec <[email protected]> wrote: >> >> GPT-3? Happy April Fools Day. >> >> Brandon >> >>> On Mar 31, 2021, at 9:47 PM, Alex Balashov <[email protected]> >>> wrote: >>> >>> For immediate release: >>> >>> GAINESVILLE, Florida (1 April 2021)--Evariste Systems, in partnership with >>> Posner | Palner Pharmaceuticals, are pleased to announce the eagerly >>> anticipated start of Phase III clinical trials of Kamailio DMQ module >>> replication. >>> >>> In this stage of the investigation of the promising replication scheme, >>> which >>> was developed in record time, DMQ will be tested in a rigourous, >>> double-blind, >>> controlled CI/CD process for large-scale efficacy and continually monitored >>> for >>> safety in shorter and longer terms. >>> >>> The now-concluded second phase established basic safety and Phase 2b >>> entailed a >>> dose-finding study for the optimal number of batched `dmq_usrloc` contacts >>> per >>> kilogram of cloud computing resource. >>> >>> The main cohort of the main sequence of the Phase III trial will enroll 380 >>> randomly selected, statistically representative Floridian SIP registrars and >>> 5700 SIP dialogs, also in the state of Florida. When asked about the >>> disparity >>> in the number of registrars versus dialogs, Alex Balashov of Evariste said, >>> "It >>> is reflective of the small number of SIP registrars in Florida; not to be >>> indelicate, but consider the median age of the population." >>> >>> As previously remarked upon in proceedings of the World SIP Organisation >>> (WSO), >>> the choice of Florida as a venue attracted some questions. We asked Fred >>> Posner >>> of Posner | Palner about the clinical background informing this choice of >>> replication study cohort: >>> >>> "Florida is a good place to find eventual consistency failures; the open >>> climate and reluctance to accept traditional data integrity science would >>> have >>> sealed the deal, but when people started to drink bleach here, I saw an >>> opportunity." >>> >>> Evariste and Posner | Palner are aiming for a US Food & Drug Administration >>> EUA >>> (Emergency Use Authorisation) for DMQ replication as a prophylactic data >>> redundancy and failover measure to ward off the development of moderate to >>> severe viral Sonus Haemorrhagic Fever symptoms. >>> >>> Phase II studies have painted a promising a picture of the DMQ >>> architecture's >>> ability to reduce moderate to severe symptoms and associated 28-day >>> mortality >>> by more than 90%, albeit over a small sample size and in enterprise patients >>> with known pre-existing comorbidities such as Session Border Controller and >>> BroadSoft Multi-System Inflammatory Syndrome. Phase III trials seek to >>> bolster >>> quantums of broader efficacy, including efficacy for localised outbreaks of >>> small to medium business softswitch. >>> >>> Of the control group, Balashov said, "They will receive a standard >>> pipe-to-/dev/null placebo protocol, but with identical '200 OK' confirmation >>> messages. We proudly developed this approach in early 2020 in consultation >>> with >>> the highest levels of the Trump presidential administration; it is called >>> TENP, or 'The Emperor's New Potion.' It is a successor to that >>> administration's >>> previous approved placebo protocol, SHTI - Small Hands, Tremendous >>> Initiatives." >>> >>> Despite speculative autism and packet fragmentation claims by Florida >>> Governor >>> Ron DeSantis, Balashov was quick to provide reassurance about side effects >>> from >>> DMQ in the Phase III trial. >>> >>> "The incidence of severe allergies to plain-text UDP was within standard >>> deviation over the mean for all insecure replication, and there's support >>> for >>> other transports on the way. Anyway, we have a robust adverse effects >>> reporting >>> system in our issue tracker and solid surveillance. Don't let partisan >>> politics >>> dissuade you from allowing request lines with the KDMQ method." >>> >>> Other industry sources have reported that DMQ is not the only replication >>> investigation undertaken by Evariste and Posner | Palner, although it is >>> the only >>> prophylactic suitable for the early infection development and inflammatory >>> phases of a broad class of SBC-complex syndromes typically afflicting >>> service >>> providers. A recent IETF preprint by the same authors has shown high-quality >>> preliminary data suggesting statistically significant improvement in >>> morbidity >>> outcomes from Perimeta and Nokia via a later-stage therapeutic intervention >>> with a monoclonal, monorepo Github cocktail administered intravenously. >>> >>> >>> -- >>> Alex Balashov | Principal | Evariste Systems LLC >>> >>> Tel: +1-706-510-6800 / +1-800-250-5920 (toll-free) >>> Web: http://www.evaristesys.com/, http://www.csrpswitch.com/ >>> _______________________________________________ >>> VoiceOps mailing list >>> [email protected] >>> https://puck.nether.net/mailman/listinfo/voiceops _______________________________________________ VoiceOps mailing list [email protected] https://puck.nether.net/mailman/listinfo/voiceops
